Tag: CoreValve Evolut R
CRT 2019: Evolut R superior to surgery at one year in intermediate-risk patients
A subanalysis from the SURTAVI trial has found that transcatheter aortic valve implantation (TAV...
TCT 2017: New data for CoreValve Evolut further support its use in intermediate-risk patients
New clinical research, presented today at the 2017 Transcatheter Cardiovascular Therapeutics (TCT)...
CoreValve Evolut can be used to treat intermediate-risk patients in the USA
Medtronic has announced that the FDA has approved the company’s self-expanding transcatheter aor...
EuroPCR 2017: No risk factor identified for early stroke events in SURTAVI trial
A review of the neurological complications that occurred after surgical aortic valve r...
ACC 2017: CoreValve non-inferior to surgery in intermediate-risk patients
Results from the SURTAVI clinical trial, which were presented today at the 2017 scientific sessi...
Medtronic receives CE mark for 34mm size CoreValve Evolut R
The CE mark has been granted to Medtronic for the 34mm-valve version of its CoreValve Evolut R, ...
TCT 2016: CoreValve Evolut R continues to be associated with good outcomes at one year
Medtronic has unveiled new clinical data that shows that patients treated with its self-expandin...
TCT 2016: Positive real-world data for CoreValve Evolut R presented
Today, Medtronic presented new positive data from two large registries aimed at evaluating 30-da...
FDA approval of 34mm CoreValve Evolut R means device is largest available TAVI valve in USA
Medtronic has announced the FDA approval and US launch of the CoreValve Evolut R 34mm valve—the ...
Health Canada grants licence to Medtronic for its CoreValve Evolut R system
Medtronic Canada has announced it has received a Health Canada licence for its recapturable, sel...
